What Generate:Biomedicines does
Generate:Biomedicines (Nasdaq: GENB) is a clinical-stage biotherapeutics company building a machine-learning-driven “Generative Biology” system it describes as programming biology to generate therapeutic proteins and related modalities. The company’s The Generate Platform is presented as a closed-loop workflow (generate, build, measure, learn) that integrates computational protein design with large-scale experimental verification, with the stated goal of increasing the speed and success probability of creating new biologic candidates across multiple modalities.
More
The company’s development strategy is led by GB-0895, an AI-engineered anti-TSLP monoclonal antibody for severe asthma (SOLAIRIA-1 and SOLAIRIA-2 Phase 3) and for which it is also evaluating additional respiratory indications such as COPD (Phase 1b). Its oncology and platform expansion efforts also include programs such as GB-4362 (an MMAE neutralizer designed to reduce circulating free MMAE associated with ADC toxicities) and an IL-18 armored MUC16 CAR-T (GB-5267) developed in collaboration with Roswell Park Comprehensive Cancer Center. Since becoming public in February 2026, Generate has continued advancing its clinical execution (including Phase 3 recruitment progress reported in August 2026) while also describing ongoing platform advancement and collaboration activity (including work through Amgen and Novartis research programs).